UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Dec

    16

    Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

    Dec

    10

    UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

    Dec

    03

    Unleashing the Power of Digital Solutions in Epilepsy Care

    UCB’s Head of Digital Business Transformation, Colin Lake speaks to the current landscape in digital business transformation and neurology.

    Dec

    03

    UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care

    Dec

    02

    Working Toward a More Equitable Future: Addressing Barriers in the Hispanic Epilepsy Community

    To better understand the experiences of Hispanic people with epilepsy and to improve our collective effort to break down barriers to equitable health outcomes, UCB is working with patients and their families, as well as health equity experts. Learn more.